| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| lanreotid 120 mg/0,5 ml i fyldt injektionssprøjte |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Lanreotide acetate (substance) |
Inferred relationship |
Some |
|
| lanreotid 60 mg/0,3 ml i fyldt injektionssprøjte |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Lanreotide acetate (substance) |
Inferred relationship |
Some |
|
| lanreotid 90 mg/0,3 ml i fyldt injektionssprøjte |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Lanreotide acetate (substance) |
Inferred relationship |
Some |
|
| lanreotid 30 mg pulver og solvens til injektionsvæske, suspension, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Lanreotide acetate (substance) |
Inferred relationship |
Some |
|
| Lanreotide (as lanreotide acetate) 30 mg powder for suspension for injection vial |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Lanreotide acetate (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely lanreotide (as lanreotide acetate) 180 milligram/1 milliliter conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Lanreotide acetate (substance) |
Inferred relationship |
Some |
1 |
| Lanreotide (as lanreotide acetate) 120 mg/mL solution for injection |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Lanreotide acetate (substance) |
Inferred relationship |
Some |
1 |
| Lanreotide (as lanreotide acetate) 240 mg/mL solution for injection |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Lanreotide acetate (substance) |
Inferred relationship |
Some |
1 |
FHIR